| Autor: |
Croda MG; Universidade Federal do Mato Grosso do Sul, Escola de Medicina, Campo Grande, Mato Grosso do Sul, Brazil., Barbosa MDS; Universidade Federal da Grande Dourados, Faculdade de Ciências da Saúde, Dourados, Mato Grosso do Sul, Brazil., Marchioro SB; Universidade Federal da Bahia, Instituto de Ciências da Saúde, Laboratório de Imunologia e Biologia Molecular, Salvador, Bahia, Brazil., Nascimento DDGD; Fundação Osvaldo Cruz, Campo Grande, Mato Grosso do Sul, Brazil., Melo ECP; Escola Nacional de Saúde Pública da Fundação Osvaldo Cruz, Rio de Janeiro, Rio de Janeiro, Brazil., Cruz OG; Fundação Oswaldo Cruz, Programa de Ciências da Computação, Rio de Janeiro, Rio de Janeiro, Brazil., Torres AJL; Universidade Federal da Bahia, Instituto de Ciências da Saúde, Laboratório de Imunologia e Biologia Molecular, Salvador, Bahia, Brazil., Oliveira LA; Universidade Federal da Grande Dourados, Faculdade de Ciências da Saúde, Laboratório de Pesquisas em Ciências da Saúde, Dourados, Mato Grosso do Sul, Brazil., Ganem F; Universitat Autònoma de Barcelona, Departament de Pediatria, d'Obstetrícia I Ginecologia i de Medicina Preventiva i de Salut Publica, Belaterra, Barcelona, Spain., Simionatto S; Universidade Federal da Grande Dourados, Faculdade de Ciências Biológicas e Ambientais, Laboratório de Pesquisas em Ciências da Saúde, Dourados, Mato Grosso do Sul, Brazil. |
| Abstrakt: |
This cross-sectional observational study that describes the epidemiological data of the first year of the COVID-19 pandemic in the Mato Grosso do Sul State, aimed to demonstrate the differences between indigenous and non-indigenous populations, characterize confirmed cases of COVID-19 according to risk factors related to ethnicity, comorbidities and their evolution and to verify the challenges in facing the disease in Brazil. SIVEP-Gripe and E-SUS-VE, a nationwide surveillance database in Brazil, from March 2020 to March 2021 in Mato Grosso do Sul state, were used to compare survivors and non-survivors from indigenous and non-indigenous populations and the epidemiological incidence curves of these populations. A total of 176,478, including 5,299 indigenous people, were confirmed. Among the indigenous population, 52.5% (confidence interval [CI] 51.2-53.9) were women, 38% (CI 36.7-39.4) were 20-39 years old, 56.7% were diagnosed by rapid antibody tests, 12.3% (CI 95%:11.5-13.2) had at least one comorbidity, and 5.3% (CI 95%:4.7-5.9) were hospitalized. In the non-indigenous patients, 56.8% were confirmed using RT-PCR, 4.4% (CI 95%:4.3-4.5) had at least one comorbidity, and 8.0% (CI 95%:7.9-8.2) were hospitalized. The majority of non-survivors were ≥60 years old (65.1% indigenous vs. 74.1% non-indigenous). The mortality in indigenous people was more than three times higher (11% vs. 2.9%). Indigenous people had a lower proportion of RT-PCR diagnoses; deaths were more frequent in younger patients and were less likely to be admitted to hospital. Mass vaccination may have controlled the incidence and mortality associated with COVID-19 in this population during the period of increased viral circulation. |
